{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:35Z","timestamp":1793431955340,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old, stage IV nasopharyngeal carcinoma male patient, who was under afatinib treatment and had experienced progressive bilateral eye dryness and tenderness on increasing afatinib from 40 mg every other day to 40 mg daily. Clinical examination noted bilateral visual acuity reduction, diffuse superficial punctate keratopathy in the right eye, and a central epithelial defect in the left eye. Seidel test results were negative for both eyes, with no corneal infiltration, lagophthalmos, anterior chamber cell precipitation, or retinal lesion. Symptoms subsequently resolved after reducing the frequency of afatinib used, along with intensive ocular hydration. In summary, this case highlighted afatinib\u2019s potential link to bilateral keratitis, and early afatinib dose adjustment with supportive medication could significantly reverse the condition.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-24-00003","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T04:00:08Z","timestamp":1708660808000},"page":"121-124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral keratitis associated with afatinib therapy"],"prefix":"10.4103","volume":"14","author":[{"given":"Ya-Tung","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Chang Gung Memorial Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chang Gung Memorial Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan"},{"name":"School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chang Gung Memorial Hospital, Chiayi, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1111\/1759-7714.15112","article-title":"Survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors:A network meta-analysis of real-world evidence","volume":"14","author":"Chang","year":"2023","journal-title":"Thorac Cancer"},{"key":"R2-20240830","first-page":"1299","article-title":"In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma","volume":"10","author":"Xue","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/ICO.0000000000001808","article-title":"Bilateral ulcerative keratitis associated with afatinib treatment for non-small-cell lung carcinoma","volume":"38","author":"McKelvie","year":"2019","journal-title":"Cornea"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000444047","article-title":"Anterior uveitis caused by ocular side effects of afatinib:A case report","volume":"7","author":"Todokoro","year":"2016","journal-title":"Case Rep Ophthalmol"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.survophthal.2014.02.004","article-title":"Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy","volume":"59","author":"Kheir","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/exer.2000.0979","article-title":"The epidermal growth factor receptor (EGFR):Role in corneal wound healing and homeostasis","volume":"72","author":"Nakamura","year":"2001","journal-title":"Exp Eye Res"},{"key":"R8-20240830","first-page":"1346","article-title":"Activation of epidermal growth factor receptor during corneal epithelial migration","volume":"41","author":"Zieske","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1188\/16.ONF.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis","year":"2016","journal-title":"Oncol Nurs Forum"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson","year":"2009","journal-title":"Cornea"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye (Lond)"},{"key":"R12-20240830","first-page":"379132","article-title":"Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib:A case report","volume":"2012","author":"Ibrahim","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours:A systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"593852","DOI":"10.3389\/fonc.2020.593852","article-title":"Case report:Afatinib treatment in a patient with NSCLC harboring a rare EGFR exon 20 mutation","volume":"10","author":"Z\u00f6chbauer-M\u00fcller","year":"2020","journal-title":"Front Oncol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/ph16010037","article-title":"Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma","volume":"16","author":"Huang","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1634\/theoncologist.2014-0103","article-title":"Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib","volume":"19","author":"Schuler","year":"2014","journal-title":"Oncologist"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.lungcan.2014.05.007","article-title":"Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis","volume":"85","author":"Popat","year":"2014","journal-title":"Lung Cancer"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma:Post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R21-20240830","first-page":"1447","article-title":"Managing Sj\u00f6gren's syndrome and non-Sj\u00f6gren Syndrome dry eye with anti-inflammatory therapy","volume":"8","author":"Coursey","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"1021713","DOI":"10.3389\/fonc.2022.1021713","article-title":"Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer:A case report","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1200\/JCO.2011.35.0694","article-title":"Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis","volume":"29","author":"Kawakami","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:11Z","timestamp":1787768591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-24-00003","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}